Swipe om te navigeren naar een ander artikel
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
To obtain health utility data to allow for cost-effectiveness analysis in groups stratified by disease progression along with health-related quality of life (HRQoL) information in Japanese prostate cancer (PC) patients.
In this cross-sectional observational study, EuroQol-5 Dimension- 5 Level (EQ-5D-5L), EuroQol Visual Analog Scale (EQ-VAS), and Functional Assessment of Cancer Therapy-Prostate (FACT-P) measures were used to examine utility, VAS scores, and disease-specific HRQoL, respectively. Scores obtained were statistically examined for the correlation among measures and domains. Parameter estimates of statistically significant factors were assessed using generalized linear models (GLM).
A total of 380 patients stratified by their disease progression status were analyzed. The numbers (%) of patients in groups stratified as having localized (L), localized progression (LP), distant metastatic (DM), and DM-castration-resistant PC (CRPC) were 275 (72.4), 40 (10.5), 27 (7.1), and 38 (10.0), respectively. EQ-5D-5L mean (standard deviation, SD) scores of L, LP, DM, and DM-CRPC in study participants were 0.87 (0.15), 0.86 (0.15), 0.85 (0.18), and 0.84 (0.17), respectively. The mean (SD) scores assessed by EQ-5D-5L, EQ-VAS, and FACT-P instruments were 0.86 (0.16), 74.6 (16.8), and 110.8 (19.6), respectively. Utility scores correlated well with FACT-P scores. Eastern Cooperative Oncology Group performance status had significant influences on all instruments’ scores.
We obtained health utility and HRQoL scores of Japanese PC patients stratified by disease progression in detail. Our results will be useful for establishing cost-effectiveness analyses in Japanese PC settings.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Hori, M., Matsuda, T., Shibata, A., Katanoda, K., Sobue, T., & Nishimoto, H. (2015). Cancer incidence and incidence rates in Japan in 2009: A study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology, 45(9), 884–891. CrossRefPubMed
Namiki, S., Ishidoya, S., Saito, S., Mitsukawa, S., Suzuki, Y., Numata, I., et al. (2008). Quality of life following endocrine therapy for advanced prostate cancer: A comparative study between LH-RH agonist 1-month depot and 3-month depot. Nihon Hinyokika Gakkai Zasshi, 99(5), 631–637. (in Japanese). PubMed
Akakura, K., Matsuzaki, K., Kobayashi, T., Kitoh, H., Mizoguchi, K., Tomikawa, G., et al. (2011). Evaluation of utility index of quality of life (QOL) in prostate cancer patients: Comparison of QOL utility index EuroQol-5D (EQ-5D) and visual analogue scale (VAS) with health-related QOL questionnaires SF-36 and EPIC. Nihon Hinyokika Gakkai Zasshi, 102(1), 9–13. (in Japanese). PubMed
Berger, M. L., Bingefors, K., Hedblom, E. C., Pashos, C. L., & Torrance, G. W. (2003). Health care cost, quality and outcomes: ISPOR Book of Terms. Lawrenceville, NJ: ISPOR.
Drummond, M., Sculpher, M., Claxton, K., Stoddart, G., & Torrance, G. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford: Oxford University Press.
Fujimura, T., Takahashi, S., Kume, H., Takeuchi, T., Kitamura, T., & Homma, Y. (2009). Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy. Internaltional Journal of Urology, 16(5), 522–525. CrossRef
Collins, R., Fenwick, E., Trowman, R., Perard, R., Norman, G., Light, K., et al. (2007). A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment, 11(2), iii–iv, xv–xviii, 1–179.
Boyd, K. A., Jones, R. J., Paul, J., Birrell, F., Briggs, A. H., & Leung, H. Y. (2015). Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. British Medical Journal Open, 5(10), e007925.
Zemplenyi, A. T., Kalo, Z., Kovacs, G., Farkas, R., Beothe, T., Banyai, D., et al. (2018). Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. European Journal of Cancer Care, 27(1), e12430. CrossRef
Brooks, R., & EuroQol Group. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72. CrossRef
Cabasés, J. (2014). Chapter 1 Introduction. In A. Szende, B. Janssen, & J. Cabases (Eds.), Self-reported population health: An international perspective based on EQ-5D (pp. 1–6). Dordrecht: Springer.
Feng, Y., Herdman, M., van Nooten, F., Cleeland, C., Parkin, D., Ikeda, S., et al. (2017). An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Quality of Life Research, 26(8), 2067–2078. CrossRefPubMedPubMedCentral
Ikeda, S., Shiroiwa, T., Igarashi, A., Noto, S., Fukuda, T., Saito, S., et al. (2015). Developing a Japanese version of the EQ-5D-5L value set. Journal of the National Institute of Public Health, 64(1), 47–55. (in Japanese).
van Reenen, M., & Janssen, B. (2015). EQ-5D-5L User Guide: Basic information on how to use the EQ-5D-5L instrument. EuroQol Research Foundation. Accessed October 13, 2018, from. https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-5L_UserGuide_2015.pdf.
D’Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., et al. (1998). Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Journals of the American Medical Association, 280(11), 969–974. CrossRef
Kitagawa, Y., Izumi, K., Sawada, K., Mizokami, A., Nakashima, K., Koshida, K., et al. (2014). Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: verification of Japanese Urological Association Guideline for prostate cancer. International Journal of Urology, 21(11), 1120–1125. CrossRefPubMed
Cancer Therapy Evaluation Program, National Cancer Institute (1999). Common terminology criteria for adverse events (CTCAE) version 4.0. Japan Clinical Oncology Group. Accessed 2 September, 2018, from http://www.jcog.jp/doctor/tool/ctcaev4.html (in Japanese).
Torvinen, S., Bergius, S., Roine, R., Lodenius, L., Sintonen, H., & Taari, K. (2016). Use of patient assessed health-related quality of life instruments in prostate cancer research: A systematic review of the literature 2002–15. International Journal of Technology Assessment in Health Care, 32(3), 97–106. CrossRefPubMed
Cheung, Y. B., Luo, N., Ng, R., & Lee, C. F. (2014). Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health and Quality of Life Outcomes, 13, 180. https://doi.org/10.1186/s12955-014-0180-6. CrossRef
Shiroiwa, T., Fukuda, T., Shimozuma, K., Kuranami, M., Suemasu, K., Ohashi, Y., et al. (2011). Comparison of EQ-5D scores among anthracycline-containing regimens followed by taxane and taxane-only regimens for node-positive breast cancer patients after surgery: The N-SAS BC 02 trial. Value in Health, 14(5), 746–751. CrossRefPubMed
- Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P
- Springer International Publishing